The enoyl-acyl carrier protein (ACP) reductase from Streptococcus pneumoniae (FabK; EC 1.3.1.9) is responsible for catalyzing the final step in each elongation cycle of fatty-acid biosynthesis. Selenomethionine-substituted FabK was purified and crystallized by the hanging-drop vapour-diffusion method at 277 K. The crystal belongs to space group P2 1 , with unit-cell parameters a = 50. 26, b = 126.70, c = 53.63 Å , = 112.46 . Diffraction data were collected to 2.00 Å resolution using synchrotron beamline BL32B2 at SPring-8. Two molecules were estimated to be present in the asymmetric unit, with a solvent content of 45.1%.
Introduction
The bacterial type II fatty-acid synthase complex comprises discrete enzyme activities encoded by discrete genes, in contrast to the multifunctional type I fatty-acid synthase in mammals . Therefore, these bacterial enzymes are attractive targets for the development of novel selective antibacterial agents (Heath et al., 2001) . Enoyl-acyl carrier protein (ACP) reductase (EC 1.3.1.9) is responsible for catalyzing the final step in each elongation cycle of bacterial type II fatty-acid biosynthesis and plays a key role in the regulation of the pathway (Heath & Rock, 1995 . Indeed, enoyl-ACP reductase activity is required for maintaining cell viability, as demonstrated from analyzing a fabI (Ts) mutant in Escherichia coli (Heath & Rock, 1995) and by using FabI-specific inhibitors. Triclosan is known to inhibit FabI, the enoyl-ACP reductase from E. coli (Heath et al., 1998) and Staphylococcus aureus Slater-Radosti et al., 2001) . The anti-tuberculosis agent isoniazid also targets the FabI homologue (InhA) of Mycobacterium tuberculosis (Qué mard et al., 1995) .
Recent genomic studies have demonstrated that an alternative triclosan-resistant enoyl-ACP reductase, FabK, is present in several clinical pathogens . For example, FabK is the sole enoyl-ACP reductase in Streptococcus pneumoniae and both FabI and FabK have been found in pathogens such as Enterococcus faecalis and Pseudomonas aeruginosa . Although novel FabI inhibitors targeting Staph. aureus have been reported by several groups (Heerding et al., 2001; Ling et al., 2004; Seefeld et al., 2001) , there are very few reports of FabK-specific inhibitors, except for a small number of compounds with weak inhibitory activity (Seefeld et al., 2003; Payne et al., 2002) . Therefore, an inhibitor designed to selectively target FabK is anticipated to have a narrow spectrum of antimicrobial activity against Strep. pneumoniae, including penicillin-resistant Strep. pneumoniae (PRSP). However, an inhibitor targeting both FabI and FabK should have a broader spectrum of activity against Staph. aureus, including methicillinresistant Staph. aureus (MRSA), Enterococci, including E. faecalis and vancomycin-resistant Enterococci (VRE), and P. aeruginosa, including the multiple drug-resistant P. aeruginosa (MDRP).
Crystal structures of FabI from several sources have been determined (Pidugu et al., 2004) , but the structure of FabK is still not available. In order to facilitate the development of selective FabK and/or dual FabK/FabI inhibitors by structure-based drug design, we have initiated a three-dimensional structure analysis of FabK from Strep. pneumoniae. In this paper, we describe the crystallization and preliminary X-ray analysis of this enzyme.
Expression and purification
The FabK gene from Strep. pneumoniae R6 (GenBank accession No. AE008418) was amplified by PCR using 5 0 -GGAATTCCATATGA-AAACGCGTATTACAGAA-3 0 as the forward primer and 5 0 -CCGC-TCGAGGTCATTTCTTACAACTCCTGT-3 0 as the reverse primer. The forward and reverse primers included an NdeI and XhoI restriction recognition site, respectively. The amplified PCR fragment was digested with NdeI and XhoI and then ligated into the pET-21b(+) expression vector (Novagen, Madison, WI, USA) at the corresponding sites. The resulting construct encoded full-length FabK (residues 1-324) with a C-terminal tag containing Leu-Glu followed by a His 6 purification tag. Nucleotide sequencing of the insert was performed to ensure that no mistakes had been introduced during the amplification process. The final construct was then transformed into the E. coli methionine auxotroph B834 (DE3) (Novagen).
The cells were cultivated in 5 l LeMaster medium (LeMaster & Richards, 1985) containing SeMet supplemented with 50 mg ml À1 ampicillin at 310 K to an OD 600 of 0.6. IPTG was added to a final concentration of 1 mM and growth was continued for an additional 3 h. The cells were harvested by centrifugation and resuspended in buffer A [50 mM sodium phosphate pH 8.0, 300 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine and 1 mM -mercaptoethanol] containing 5 mM imidazole and 0.1 mg ml À1 lysozyme. The mixture was incubated for 30 min at ice temperature and then sonicated on ice. The cell lysates were centrifuged at 27 000g for 30 min in order to remove cell debris. The supernatant was filtered with a 0.22 mm filter and loaded onto a column packed with 30 ml Ni-NTA Agarose beads (Qiagen, Valencia, CA, USA) equilibrated with buffer A containing 5 mM imidazole. The column was washed with buffer A containing 20 mM imidazole and bound protein was eluted with buffer A containing 200 mM imidazole. Fractions containing FabK were identified by SDS-PAGE and subsequently pooled and dialyzed against buffer B [50 mM Tris-HCl pH 7.5, 50 mM NH 4 Cl, 1 mM PMSF, 1 mM benzamidine and 1 mM dithiothreitol (DTT)]. The dialysate was loaded onto a POROS HQ/20 column (PerSeptive Biosystems, Framingham, MA, USA) equilibrated with buffer B. The column was washed with buffer B and bound proteins were eluted with a linear gradient of 0-500 mM NaCl in buffer B. Fractions containing FabK were identified by SDS-PAGE and subsequently pooled. Ammonium sulfate was added to the pooled fractions to a final concentration of 2.0 M and the mixture was applied onto a Resource PHE 6 ml column (Amersham Biosciences, Uppsala, Sweden) equilibrated with buffer B containing 2.0 M ammonium sulfate. After the column had been washed with buffer B containing 2.0 M ammonium sulfate, the protein was eluted with a decreasing linear gradient of 2.0-0 M ammonium sulfate in buffer B. Fractions containing FabK were identified by SDS-PAGE and subsequently concentrated by ultrafiltration using an Amicon Ultra-15 centrifugal filter device with a 30K NMWL (Millipore, Bedford, MA, USA). The concentrated sample was loaded onto a HiLoad 16/60 Superdex 75 prep-grade sizeexclusion column (Amersham Biosciences) equilibrated with buffer B containing 150 mM NaCl. The peak fractions were pooled and then concentrated to 10 mg ml À1 and the buffer exchanged to 10 mM Tris-HCl pH 7.5, 100 mM NH 4 Cl, 5 mM DTT and 5 mM NADH by ultrafiltration as described earlier.
Crystallization
SeMet-substituted FabK crystals were grown by the hanging-drop vapour-diffusion method at 277 K. Initial screening was performed using sparse-matrix screens (Jancarik & Kim, 1991) based on the commercially available Crystal Screens I and II (Hampton Research, Laguna Niguel, CA, USA) and Wizard I and II (Emerald Biostructures, Bainbridge Island, WA, USA) and additional crystallography reagent kits. Several crystal forms were obtained and the most promising crystallization condition was optimized. 2 ml protein solution (10 mg ml À1 ) was mixed with an equal volume of reservoir solution and equilibrated against 0.5 ml reservoir solution at 277 K. Microcrystals were obtained with reservoir solution containing 0.1 M MES pH 5.5-7.0, 0.1 M NH 4 Cl, 0.2 M CaCl 2 , 8-15%(v/v) MPD, 8-15%(w/v) PEG 1000 and 5 mM DTT. Several microcrystals were washed with reservoir solution and then crushed to produce microseeds, which were stored in 10 ml reservoir solution. For microseeding experiments, the seed stock was diluted 10 4 -fold to 10 6 -fold with the reservoir solution. A 2 ml aliquot of this prepared precipitant was mixed with 2 ml protein solution to make the droplet. Finally, thin plate-shaped crystals of SeMet-substituted FabK were obtained with average dimensions of approximately 0.05 Â 0.30 Â 0.50 mm (Fig. 1) . 
Data collection
A crystal of SeMet-substituted FabK was transferred to a reservoir solution with 15%(w/v) glycerol as a cryoprotectant for several seconds and flash-cooled in a cryostream of N 2 gas at 100 K. A multiple-wavelength anomalous dispersion (MAD) data set was collected on the pharmaceutical industry beamline (BL32B2) at the SPring-8 synchrotron facility (Hyogo, Japan) using a Jupiter 210 CCD detector (Rigaku, Tokyo, Japan). The values of Áf 0 and Áf 00 were determined experimentally with X-ray absorption fine-structure (XAFS) spectroscopy after the mounting the crystal on the beamline. The oscillation ranges were 220 and three wavelengths were used in the sequence high-energy remote (0.90000 Å ), peak (0.97888 Å ) and edge (0.97932 Å ), with the oscillation per frame being 1 in each case. All X-ray diffraction data were integrated and scaled using the CrystalClear package (Rigaku). Diffraction data statistics are summarized in Table 1 . The space group of the SeMet-substituted FabK crystal was determined to be monoclinic P2 1 . Assuming the presence of two molecules of FabK in the asymmetric unit, the value of the Matthews coefficient V M is 2.24 Å 3 Da À1 , corresponding to a solvent content of 45.1%, both of which are within the normal range of values for protein crystals (Matthews, 1968) . The search for Se-atom sites and the structure determination of FabK using the MAD method is now in progress.
